+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Bispecific Antibodies"

Monoclonal Antibody Therapeutics Market Report 2026 - Product Thumbnail Image

Monoclonal Antibody Therapeutics Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
Antibody Drug Conjugate - Competitive Landscape, 2026 - Product Thumbnail Image

Antibody Drug Conjugate - Competitive Landscape, 2026

  • Report
  • April 2026
  • 280 Pages
  • Global
From
From
CTLA-4 Inhibitors - Competitive Landscape, 2026 - Product Thumbnail Image

CTLA-4 Inhibitors - Competitive Landscape, 2026

  • Report
  • January 2026
  • 220 Pages
  • Global
From
From
T-Cell Malignancies - Pipeline Insight, 2025 - Product Thumbnail Image

T-Cell Malignancies - Pipeline Insight, 2025

  • Drug Pipelines
  • July 2025
  • 280 Pages
  • Global
From
Esophageal Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Esophageal Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • July 2025
  • 280 Pages
  • Global
From
Cancer Cachexia - Pipeline Insight, 2025 - Product Thumbnail Image

Cancer Cachexia - Pipeline Insight, 2025

  • Clinical Trials
  • July 2025
  • 80 Pages
  • Global
From
From
From
From
From
From
Checkpoint Inhibitors - Competitive Landscape, 2026 - Product Thumbnail Image

Checkpoint Inhibitors - Competitive Landscape, 2026

  • Report
  • January 2026
  • 180 Pages
  • Global
From
Antibody Discovery Market Report and Forecast 2025-2034 - Product Thumbnail Image

Antibody Discovery Market Report and Forecast 2025-2034

  • Report
  • June 2025
  • 400 Pages
  • Global
From
Loading Indicator

Bispecific antibodies are a type of biotechnology that are used to target two different antigens simultaneously. They are engineered to bind to two different epitopes on the same or different antigens, allowing them to act as a bridge between two different cells or molecules. Bispecific antibodies have been used in a variety of therapeutic applications, including cancer immunotherapy, autoimmune diseases, and infectious diseases. Bispecific antibodies have the potential to improve the efficacy of existing treatments and to develop new treatments for diseases that have not yet been addressed. They can also be used to target multiple antigens at once, allowing for more efficient and effective treatments. The bispecific antibodies market is expected to grow significantly in the coming years due to the increasing demand for targeted therapies and the development of new technologies. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more